miR-362-3p targets nemo-like kinase and functions as a tumor suppressor in renal cancer cells

Zou,Xiaowen; Zhong,Jianhua; Li,Jiaqiang; Su,Zhengming; Chen,Yan; Deng,Wanxin; Li,Yuchi; Lu,Siheng; Lin,Youcheng; Luo,Liya; Li,Zesong; Cai,Zhiming; Tang,Aifa

doi:10.3892/mmr.2015.4632

miR-362-3p targets nemo-like kinase and functions as a tumor suppressor in renal cancer cells

Authors:
- Xiaowen Zou
- Jianhua Zhong
- Jiaqiang Li
- Zhengming Su
- Yan Chen
- Wanxin Deng
- Yuchi Li
- Siheng Lu
- Youcheng Lin
- Liya Luo
- Zesong Li
- Zhiming Cai
- Aifa Tang
View Affiliations

Affiliations: National‑Regional Key Technology Engineering Laboratory for Clinical Application of Cancer Genomics, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518000, P.R. China, Department of Pediatric Urinary Surgery, Shenzhen Children's Hospital, Shenzhen, Guangdong 518000, P.R. China, Department of Clinical Medicine, Shantou University Medical College, Shantou, Guangdong 515063, P.R. China, Department of Urology, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong 510282, P.R. China
Published online on: November 30, 2015 https://doi.org/10.3892/mmr.2015.4632
Pages: 994-1002

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs) have been demonstrated to exhibit abnormal expression patterns in various types of human cancer. The aim of the present study was to identify a novel tumor suppressor microRNA (miR) and investigate its physiological function and mechanism in renal cell carcinoma (RCC). The expression levels of miRNA (miR)‑362‑3p expres were measured in 47 pairs of RCC and adjacent normal tissue samples, using reverse transcription-quantitative polymerase chain reaction analysis. In addition, miR‑362‑3p was transfected into renal cancer cells to investigate its role in the regulation of cell proliferation, migration, invasion, apoptosis and cell cycle. Identification of the target gene of miR‑362‑3p was performed using luciferase reporter assays and western blot analyses. The results demonstrated that the expression levels of miR‑362‑3p were downregulated in the RCC tissue samples, compared with the adjacent normal tissue samples. The upregulation of miR‑362‑3p using a synthesized mimic suppressed the proliferation, migration and invasion of the renal cancer cells, and induced cell apoptosis and G1 phase arrest. Further experiments demonstrated that the overexpression of miR‑362‑3p resulted in decrease expression levels of nemo-like kinase. These results suggested that miR-362-3p functions as a tumor suppressor in RCC, and may serve as a potential molecular target in the treatment of RCC.

View Figures

View References

1	Grange C, Collino F, Tapparo M and Camussi G: Oncogenic micro-RNAs and renal cell carcinoma. Front Oncol. 4:492014. View Article : Google Scholar : PubMed/NCBI
2	Lopez-Beltran A, Carrasco JC, Cheng L, Scarpelli M, Kirkali Z and Montironi R: 2009 update on the classification of renal epithelial tumors in adults. Int J Urol. 16:432–443. 2009. View Article : Google Scholar : PubMed/NCBI
3	Rini BI, Campbell SC and Escudier B: Renal cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
4	van Spronsen DJ, de Weijer KJ, Mulders PF and De Mulder PH: Novel treatment strategies in clear-cell metastatic renal cell carcinoma. Anticancer Drugs. 16:709–717. 2005. View Article : Google Scholar : PubMed/NCBI
5	Reeves DJ and Liu CY: Treatment of metastatic renal cell carcinoma. Cancer Chemother Pharmacol. 64:11–25. 2009. View Article : Google Scholar : PubMed/NCBI
6	Janzen NK, Kim HL, Figlin RA and Belldegrun AS: Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 30:843–852. 2003. View Article : Google Scholar : PubMed/NCBI
7	Shao Y, Zhang SQ, Quan F, Zhang PF and Wu SL: MicroRNA-145 inhibits the proliferation, migration and invasion of the human TCA8113 oral cancer line. Oncol Lett. 6:1636–1640. 2013.PubMed/NCBI
8	Yang L, Wang YL, Liu S, Zhang PP, Chen Z, Liu M and Tang H: miR-181b promotes cell proliferation and reduces apoptosis by repressing the expression of adenylyl cyclase 9 (AC9) in cervical cancer cells. FEBS Lett. 588:124–130. 2014. View Article : Google Scholar
9	Billeter AT, Barnett RE, Druen D, Polk HC Jr and van Berkel VH: MicroRNA as a new factor in lung and esophageal cancer. Semin Thorac Cardiovasc Surg. 24:155–165. 2012. View Article : Google Scholar : PubMed/NCBI
10	Eulalio A, Huntzinger E and Izaurralde E: Getting to the root of miRNA-mediated gene silencing. Cell. 132:9–14. 2008. View Article : Google Scholar : PubMed/NCBI
11	Lytle JR, Yario TA and Steitz JA: Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5′UTR as in the 3′UTR. Proc Natl Acad Sci USA. 104:9667–9672. 2007. View Article : Google Scholar
12	Wightman B, Bürglin TR, Gatto J, Arasu P and Ruvkun G: Negative regulatory sequences in the lin-14 3′-untranslated region are necessary to generate a temporal switch during Caenorhabditis elegans development. Genes Dev. 5:1813–1824. 1991. View Article : Google Scholar : PubMed/NCBI
13	Lal A, Navarro F, Maher CA, Maliszewski LE, Yan N, O'Day E, Chowdhury D, Dykxhoorn DM, Tsai P, Hofmann O, et al: miR-24 Inhibits cell proliferation by targeting E2F2, MYC and other cell-cycle genes via binding to 'seedless' 3′UTR microRNA recognition elements. Mol Cell. 35:610–625. 2009. View Article : Google Scholar : PubMed/NCBI
14	Lerner M, Lundgren J, Akhoondi S, Jahn A, Ng HF, Akbari Moqadam F, Oude Vrielink JA, Agami R, Den Boer ML, Grandér D and Sangfelt O: MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression. Cell Cycle. 10:2172–2183. 2011. View Article : Google Scholar : PubMed/NCBI
15	Ebert PJ, Jiang S, Xie J, Li QJ and Davis MM: An endogenous positively selecting peptide enhances mature T cell responses and becomes an autoantigen in the absence of microRNA miR-181a. Nat Immunol. 10:1162–1169. 2009. View Article : Google Scholar : PubMed/NCBI
16	Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, Newman J, Bronson RT, Crowley D, Stone JR, et al: Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell. 132:875–886. 2008. View Article : Google Scholar : PubMed/NCBI
17	Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, et al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 102:13944–13949. 2005. View Article : Google Scholar : PubMed/NCBI
18	Curtale G, Citarella F, Carissimi C, Goldoni M, Carucci N, Fulci V, Franceschini D, Meloni F, Barnaba V and Macino G: An emerging player in the adaptive immune response: MicroRNA-146a is a modulator of IL-2 expression and activation-induced cell death in T lyzmphocytes. Blood. 115:265–273. 2010. View Article : Google Scholar
19	Yu Z, Ni L, Chen D, et al: Identification of miR-7 as an oncogene in renal cell carcinoma. J Mol Histol. 44:669–677. 2013. View Article : Google Scholar : PubMed/NCBI
20	Peng H, Luo J, Hao H, Hu J, Xie SK, Ren D and Rao B: MicroRNA-100 regulates SW620 colorectal cancer cell proliferation and invasion by targeting RAP1B. Oncol Rep. 31:2055–2062. 2014.PubMed/NCBI
21	Xie J, Chen M, Zhou J, Mo MS, Zhu LH, Liu YP, Gui QJ, Zhang L and Li GQ: miR-7 inhibits the invasion and metastasis of gastric cancer cells by suppressing epidermal growth factor receptor expression. Oncol Rep. 31:1715–1722. 2014.PubMed/NCBI
22	Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005. View Article : Google Scholar : PubMed/NCBI
23	Babashah S and Soleimani M: The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis. Eur J Cancer. 47:1127–1137. 2011. View Article : Google Scholar : PubMed/NCBI
24	Seca H, Almeida GM, Guimarães JE and Vasconcelos MH: miR signatures and the role of miRs in acute myeloid leukaemia. Eur J Cancer. 46:1520–1527. 2010. View Article : Google Scholar : PubMed/NCBI
25	Schickel R, Boyerinas B, Park SM and Peter ME: MicroRNAs: Key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene. 27:5959–5974. 2008. View Article : Google Scholar : PubMed/NCBI
26	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
27	Müller S and Nowak K: Exploring the miRNA-mRNA regulatory network in clear cell renal cell carcinomas by next-generation sequencing expression profiles. Biomed Res Int. 2014:9484082014. View Article : Google Scholar : PubMed/NCBI
28	Osanto S, Qin Y, Buermans HP, Berkers J, Lerut E, Goeman JJ and van Poppel H: Genome-wide microRNA expression analysis of clear cell renal cell carcinoma by next generation deep sequencing. PLoS One. 7:e382982012. View Article : Google Scholar : PubMed/NCBI
29	Zhou L, Chen J, Li Z, Li X, Hu X, Huang Y, Zhao X, Liang C, Wang Y, Sun L, et al: Integrated profiling of microRNAs and mRNAs: MicroRNAs located on Xq27.3 associate with clear cell renal cell carcinoma. PLoS One. 5:e152242010. View Article : Google Scholar
30	Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
31	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
32	Su Z, Chen D, Zhang E, et al: MicroRNA-509-3p inhibits cancer cell proliferation and migration by targeting the mitogen-activated protein kinase kinase kinase 8 oncogene in renal cell carcinoma. Mol Med Rep. 12:1535–1543. 2015.PubMed/NCBI
33	Patel C, Ahmed A and Ellsworth P: Renal cell carcinoma: A reappraisal. Urol Nurs. 32:182–190. 2012.PubMed/NCBI
34	Yang SF, Hsu HL, Chao TK, Hsiao CJ, Lin YF and Cheng CW: Annexin A2 in renal cell carcinoma: Expression, function and prognostic significance. Urol Oncol. 33:e11–e21. 2015. View Article : Google Scholar
35	Lang Y, Xu S, Ma J, Wu J, Jin S, Cao S and Yu Y: MicroRNA-429 induces tumorigenesis of human non-small cell lung cancer cells and targets multiple tumor suppressor genes. Biochem Biophys Res Commun. 450:154–159. 2014. View Article : Google Scholar : PubMed/NCBI
36	Huang Y, Dai Y, Yang J, Chen T, Yin Y, Tang M, Hu C and Zhang L: Microarray analysis of microRNA expression in renal clear cell carcinoma. Eur J Surg Oncol. 35:1119–1123. 2009. View Article : Google Scholar : PubMed/NCBI
37	Luthra R, Chen H, Roy-Chowdhuri S and Singh RR: Next-generation sequencing in clinical molecular diagnostics of cancer: Advantages and challenges. Cancers (Basel). 7. pp. 2023–2036. 2015, View Article : Google Scholar
38	Christensen LL, Tobiasen H, Holm A, Schepeler T, Ostenfeld MS, Thorsen K, Rasmussen MH, Birkenkamp-Demtroeder K, Sieber OM, Gibbs P, et al: MiRNA-362-3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer. Int J Cancer. 133:67–78. 2013. View Article : Google Scholar : PubMed/NCBI
39	Van Wynsberghe PM, Chan SP, Slack FJ and Pasquinelli AE: Analysis of microRNA expression and function. Methods Cell Biol. 106:219–252. 2011. View Article : Google Scholar : PubMed/NCBI
40	Ishitani T and Ishitani S: Nemo-like kinase, a multifaceted cell signaling regulator. Cell Signal. 25:190–197. 2013. View Article : Google Scholar
41	Yuzugullu H, Benhaj K, Ozturk N, Senturk S, Celik E, Toylu A, Tasdemir N, Yilmaz M, Erdal E, Akcali KC, et al: Canonical wnt signaling is antagonized by noncanonical wnt5a in hepato-cellular carcinoma cells. Mol Cancer. 8:902009. View Article : Google Scholar
42	Stevens KN, Kelemen LE, Wang X, Fridley BL, Vierkant RA, Fredericksen Z, Armasu SM, Tsai YY, Berchuck A, Narod SA, et al: Common variation in nemo-like kinase is associated with risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 21:523–528. 2012. View Article : Google Scholar : PubMed/NCBI
43	Yasuda J, Tsuchiya A, Yamada T, Sakamoto M, Sekiya T and Hirohashi S: Nemo-like kinase induces apoptosis in DLD-1 human colon cancer cells. Biochem Biophys Res Commun. 308:227–233. 2003. View Article : Google Scholar : PubMed/NCBI
44	Emami KH, Brown LG, Pitts TE, Sun X, Vessella RL and Corey E: Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells. Prostate. 69:1481–1492. 2009. View Article : Google Scholar : PubMed/NCBI
45	Jung KH, Kim JK, Noh JH, Eun JW, Bae HJ, Xie HJ, Ahn YM, Park WS, Lee JY and Nam SW: Targeted disruption of Nemo-like kinase inhibits tumor cell growth by simultaneous suppression of cyclin D1 and CDK2 in human hepatocellular carcinoma. J Cell Biochem. 110:687–696. 2010. View Article : Google Scholar : PubMed/NCBI
46	Cui G, Li Z, Shao B, Zhao L, Zhou Y, Lu T, Wang J, Shi X, Wang J, Zuo G, et al: Clinical and biological significance of nemo-like kinase expression in glioma. J Clin Neurosci. 18:271–275. 2011. View Article : Google Scholar